NCT01552629View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 5, 2012

Primary Completion Date

August 28, 2013

Study Completion Date

August 28, 2013

Conditions
Atopic Dermatitis
Interventions
DRUG

QGE031

DRUG

Placebo

DRUG

Cyclosporine A

Trial Locations (4)

24105

Novartis Investigative Site, Kiel

53105

Novartis Investigative Site, Bonn

Unknown

Novartis Investigative Site, Vienna

06202

Novartis Investigative Site, Nice

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY